Residency · Residency · Dermatology
Post-Inflammatory Hyperpigmentation and Hypopigmentation
Introduction
Post-inflammatory pigmentary changes are among the most common dermatologic complaints, particularly in patients with Fitzpatrick skin types III-VI. These acquired alterations in skin color occur as a sequela of cutaneous inflammation or injury and, while not medically dangerous, often cause greater distress than the inciting condition itself. Effective management requires treating the underlying inflammatory process, minimizing further pigmentary disruption, and employing evidence-based depigmenting or repigmenting strategies.
Post-Inflammatory Hyperpigmentation (PIH)
Epidemiology
PIH affects all skin types but is disproportionately common and severe in darker skin (Fitzpatrick IV through VI). It is one of the top five reasons for dermatology consultation in patients of African, Hispanic, Asian, and Middle Eastern descent. Common inciting conditions include acne vulgaris (the most frequent cause in younger patients), eczema, psoriasis, cutaneous lupus, lichen planus, drug eruptions, trauma, and procedural interventions.
Pathogenesis
In epidermal PIH, inflammatory mediators (prostaglandins, leukotrienes, thromboxanes, reactive oxygen species) stimulate melanocytes to increase melanin production and transfer to surrounding keratinocytes. PGE2 and LTB4 directly upregulate tyrosinase activity, while ET-1, SCF, and alpha-MSH released by damaged keratinocytes activate melanocyte proliferation and melanogenesis. The result is increased melanin within the epidermis, which appears brown clinically. In dermal PIH (melanin incontinence), severe inflammation damages the basal layer and basement membrane, causing melanin to "fall" into the dermis where it is phagocytosed by dermal melanophages. This produces blue-gray or slate-gray pigmentation that is clinically deeper-appearing and much more resistant to treatment. Dermal melanin may persist for years to indefinitely. Most PIH is mixed (epidermal plus dermal).
Clinical Features
PIH presents as macules or patches of darkened skin at the site of prior inflammation, corresponding precisely to the distribution of the antecedent condition. Color ranges from tan or brown (epidermal) to blue-gray (dermal). Wood's lamp examination shows enhanced contrast with epidermal PIH and minimal to no enhancement with dermal PIH. Distribution mirrors the underlying disease: acne PIH on the face, eczema PIH in flexural areas. PIH may persist for months to years, with darker skin types experiencing more persistent changes.
Diagnosis
The diagnosis is clinical, based on a history of preceding inflammation and characteristic pigmentary changes. Wood's lamp helps differentiate epidermal from dermal pigment. Dermoscopy shows brown structureless areas in epidermal PIH and blue-gray granules and dots (dermal melanophages) in dermal PIH. Biopsy is rarely needed but shows melanin in the basal layer and suprabasal keratinocytes in epidermal PIH, or melanin-laden macrophages in the upper dermis in dermal PIH.
<image>Clinical photographs showing post-inflammatory hyperpigmentation in varying skin types: brown macules on the face following acne vulgaris in a Fitzpatrick type IV patient, slate-gray patches following lichen planus in a Fitzpatrick type V patient, and corresponding Wood's lamp images demonstrating epidermal enhancement versus dermal non-enhancement</image>
Management of PIH
Treat the Underlying Condition First
PIH cannot be effectively treated while the inciting inflammation is ongoing. Aggressive control of the primary dermatosis (acne, eczema, psoriasis) is the essential first step. Anti-inflammatory treatments that minimize PIH risk should be selected (for example, avoiding cryotherapy, aggressive peels, or ablative lasers in PIH-prone patients).
Photoprotection
Broad-spectrum sunscreen SPF 30 or higher with visible light protection (tinted with iron oxides) is mandatory. UV exposure darkens existing PIH and stimulates additional melanogenesis. Sun protection alone can lead to meaningful improvement over time.
Topical Depigmenting Agents
Hydroquinone 4% is the most effective topical agent, a tyrosinase inhibitor applied nightly for 8 to 12 weeks and cycled to prevent ochronosis. Azelaic acid 15 to 20% inhibits tyrosinase, has anti-inflammatory properties, is safe for long-term use and in pregnancy, and is particularly effective for acne-related PIH. Topical retinoids (tretinoin 0.025 to 0.1%, adapalene 0.1 to 0.3%) enhance epidermal turnover, facilitate melanin dispersion, and complement other depigmenting agents, though irritation may temporarily worsen PIH. Vitamin C (L-ascorbic acid 10 to 20%) is an antioxidant with mild tyrosinase inhibition that is well-tolerated and best used as an adjunct. Niacinamide 4 to 5% inhibits melanosome transfer from melanocytes to keratinocytes with excellent tolerability. Tranexamic acid (topical 3 to 5%) has emerging evidence for PIH efficacy. Kojic acid 2% and arbutin (alpha-arbutin 2%) are milder alternatives.
Combination Therapy
The most effective approach combines multiple agents addressing different steps of melanogenesis. An example regimen includes hydroquinone 4% plus tretinoin 0.025% plus azelaic acid 15% (rotated or applied at different times of day) with daily tinted sunscreen. The modified Kligman formula (hydroquinone plus tretinoin plus topical corticosteroid) is effective but requires limiting corticosteroid duration.
Chemical Peels
Superficial peels (glycolic acid 20 to 50%, salicylic acid 20 to 30%, mandelic acid, lactic acid) are useful adjuncts for epidermal PIH. They should be performed with caution in darker skin types, starting with lower concentrations and shorter contact times. Salicylic acid peels are preferred in darker skin due to lower risk of causing additional PIH. Medium and deep peels should be avoided in Fitzpatrick IV through VI due to high risk of paradoxical worsening.
Laser and Light-Based Therapies
These carry a high risk of worsening PIH in darker skin types and should be approached with extreme caution. QS Nd:YAG 1064 nm is the safest laser wavelength for darker skin, and low-fluence treatments may help dermal PIH. Fractional non-ablative lasers (1550 nm) have some evidence in PIH with lower risk than ablative approaches. Ablative lasers are generally contraindicated for PIH in darker skin. Test spots should always be performed before treating larger areas.
| Feature | Epidermal PIH | Dermal PIH | PIHo | Vitiligo |
|---|---|---|---|---|
| Color | Tan/brown | Blue-gray/slate | Lighter than normal | Chalk-white |
| Wood's lamp | Enhanced | Not enhanced | Mild enhancement | Bright white fluorescence |
| Melanocytes | Present, hyperactive | Present | Present, hypoactive | Absent |
| Duration | Months | Years (may be permanent) | Weeks to months (self-limited) | Progressive unless treated |
| Treatment response | Good (topicals) | Poor (deep) | Usually self-resolving | Variable |
Post-Inflammatory Hypopigmentation (PIHo)
Pathogenesis
Post-inflammatory hypopigmentation results from inflammatory damage to melanocytes that reduces melanin production without complete melanocyte destruction. Melanocytes are present but functionally impaired (with decreased tyrosinase activity and reduced melanosome transfer). This distinguishes PIHo from vitiligo, where melanocytes are completely absent. It is more common in darker skin types where contrast with surrounding skin is more visible.
Common Causes
Atopic dermatitis is one of the most common causes, especially in children with darker skin. Other causes include psoriasis (hypopigmentation in resolving plaques), pityriasis alba (poorly defined, hypopigmented, scaly patches on the face in children, often associated with atopy), seborrheic dermatitis, and pityriasis versicolor (Malassezia-induced hypopigmented macules on the trunk, where the organism produces azelaic acid that inhibits tyrosinase). Procedural causes include post-cryotherapy and post-laser hypopigmentation (especially IPL and ablative resurfacing). Less common but important causes to exclude include sarcoidosis, mycosis fungoides, and morphea.
Clinical Features
PIHo presents as lighter-than-normal macules or patches at the site of prior inflammation. The pigment is reduced but not absent (not chalk-white), which distinguishes it from vitiligo. Wood's lamp shows mild enhancement in hypopigmented lesions but not the bright white fluorescence of complete depigmentation seen in vitiligo. Distribution is usually symmetric, following the distribution of the antecedent condition.
Diagnosis
The diagnosis is clinical, based on a history of prior inflammatory dermatosis plus hypopigmented macules at the same sites. Wood's lamp distinguishes hypopigmentation (mild enhancement) from depigmentation (bright white fluorescence). Biopsy is rarely needed but shows melanocytes that are present with reduced melanin content and reduced melanosome transfer. KOH preparation should be performed to exclude pityriasis versicolor if the distribution is suggestive.
Differential Diagnosis
Vitiligo shows complete depigmentation that is chalk-white on Wood's lamp, is autoimmune and progressive. Pityriasis versicolor presents with fine scale, positive KOH, and trunk distribution. Hypopigmented mycosis fungoides shows patches in non-sun-exposed areas (buttocks, trunk), with biopsy revealing atypical lymphocytes. Idiopathic guttate hypomelanosis produces small, well-demarcated, porcelain-white macules on sun-exposed extremities related to photoaging. Progressive macular hypomelanosis shows symmetric, confluent hypopigmented macules on the trunk in young adults, associated with cutaneous Propionibacterium acnes.
Management of PIHo
The underlying inflammatory condition should be treated first, as melanocyte function often recovers once inflammation resolves. Natural repigmentation occurs over weeks to months in most cases, and reassurance is often the most important intervention. Controlled sun exposure with brief UV exposure can stimulate melanocyte activity and repigmentation but must be balanced against photoprotection needs. Topical calcineurin inhibitors (tacrolimus 0.1%) may promote repigmentation by modulating the immune microenvironment, supported by limited evidence. Phototherapy (NB-UVB) is effective for widespread PIHo by stimulating melanocyte proliferation and melanogenesis. Excimer laser (308 nm) provides targeted phototherapy for focal PIHo. Topical retinoids may help by normalizing melanocyte function and epidermal turnover. Cosmetic camouflage is important for patient quality of life during the recovery period.
<image>Clinical comparison panel showing post-inflammatory hypopigmentation: hypopigmented patches on the face following resolution of atopic dermatitis in a child, pityriasis alba with poorly defined facial hypopigmentation, and pityriasis versicolor with hypopigmented macules on the trunk, each with corresponding Wood's lamp findings</image>
Key Clinical Pearls
Always treat the underlying inflammatory condition first, as PIH and PIHo cannot resolve while active inflammation persists. Wood's lamp is the simplest tool to distinguish epidermal PIH (enhanced) from dermal PIH (not enhanced) and hypopigmentation from depigmentation (vitiligo). PIH in darker skin types is best treated with combination topical therapy, as no single agent is sufficient. Aggressive procedural interventions (deep peels, ablative lasers, cryotherapy) should be avoided in Fitzpatrick IV through VI patients, as these carry high risk of causing additional PIH. Post-inflammatory hypopigmentation is usually self-limited and recoverable because melanocytes are present but dysfunctional, unlike vitiligo where melanocytes are destroyed.
References
- Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
- Callender VD, St Surin-Lord S, Davis EC, Maclin M. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol. 2011;12(2):87-99.
- Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011;36(7):708-714.
- Taylor SC, Burgess CM, Callender VD. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial. Dermatol Surg. 2002;28(12):1097-1100.
